Medicare Advantage Plan Proposed Use Of Step Therapy For Part B Drugs

September 17, 2018

Via: Forbes

Payers must balance patient access to biopharmaceuticals and cost containment. A public payer such as Medicare and its contractors is no different in this regard. Yet, payers may in some cases be constrained in the kinds of methods they can deploy in the private versus public sector. Until now, payers and regional contractors in charge of managing physician-administered drugs covered under Medicare Part B had limited options available to them.

Read More on Forbes